Isabella G. Martinez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Isabella G. Martinez has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Grace Freed
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York
25 shared publications - Clifford Chao
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
24 shared publications - Dan Hasson
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
24 shared publications - Ke Wang
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
24 shared publications - Levan Mekerishvili
Division of Hematology and Medical Oncology, Department of Medicine and Meyer Cancer Center, Weill Cornell Medicine, New York, NY
24 shared publications - Mimi Zhang
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
24 shared publications
Latest Publications
- 24 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (22) , 7690-7701
A CRISPR-based humanized model reveals a cooperative role of STAG2 loss in familial GATA2-deficient MDS progression
Myelodysplastic syndrome (MDS) is a heterogeneous myeloid malignant neoplasm driven by hematopoietic stem cell dysfunction, leading to ineffective hematopoiesis and cytopenias. Familial GATA2 deficiency is the most common cause of MDS in adolescents, with progression often accelerated by co-occurring mutations, notably STAG2 loss of function. Using CRISPR/Cas9-mediated genome engineering in primary human fetal liver–derived hematopoietic stem cells and xenotransplantation in mice, we modeled GATA2-deficient MDS with acquired STAG2 loss to investigate disease initiation and progression. Although GATA2 deficiency alone had minimal short-term impact in our model, combined GATA2 deficiency and STAG2 loss increased hematopoietic stem cell maintenance and self-renewal, induced a myeloid-lineage bias, and expanded primitive progenitors. Single-cell transcriptional profiling revealed upregulation of stemness-associated genes and inflammatory pathways. This humanized model faithfully recapitulates high-risk GATA2-deficient MDS, providing mechanistic insights into how cooperative mutations drive stem cell expansion, inflammatory signaling, and myeloid skewing.
- 24 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (22) , 7690-7701
A CRISPR-based humanized model reveals a cooperative role of STAG2 loss in familial GATA2-deficient MDS progression
Myelodysplastic syndrome (MDS) is a heterogeneous myeloid malignant neoplasm driven by hematopoietic stem cell dysfunction, leading to ineffective hematopoiesis and cytopenias. Familial GATA2 deficiency is the most common cause of MDS in adolescents, with progression often accelerated by co-occurring mutations, notably STAG2 loss of function. Using CRISPR/Cas9-mediated genome engineering in primary human fetal liver–derived hematopoietic stem cells and xenotransplantation in mice, we modeled GATA2-deficient MDS with acquired STAG2 loss to investigate disease initiation and progression. Although GATA2 deficiency alone had minimal short-term impact in our model, combined GATA2 deficiency and STAG2 loss increased hematopoietic stem cell maintenance and self-renewal, induced a myeloid-lineage bias, and expanded primitive progenitors. Single-cell transcriptional profiling revealed upregulation of stemness-associated genes and inflammatory pathways. This humanized model faithfully recapitulates high-risk GATA2-deficient MDS, providing mechanistic insights into how cooperative mutations drive stem cell expansion, inflammatory signaling, and myeloid skewing.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia
Metabolomic Profiling in NUP98::NSD1 AML
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia
Metabolomic Profiling in NUP98::NSD1 AML
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia
Predicted off-targets of CRISPR/Cas9 genome editing
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia
Predicted off-targets of CRISPR/Cas9 genome editing
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia
Comparison of chromatin accessibility of motifs in LMPP/Early GMPs under different conditions
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia
Comparison of chromatin accessibility of motifs in LMPP/Early GMPs under different conditions
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia
PRDM16 Regulates Leukemic Stemness, Metabolism, and Quiescence in NUP98::NSD1/WT1ko AML Part 2
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia
PRDM16 Regulates Leukemic Stemness, Metabolism, and Quiescence in NUP98::NSD1/WT1ko AML Part 2
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia
Validation of NUP98::NSD1 Fusion and WT1 Knockout in Human HSPCs
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia
Validation of NUP98::NSD1 Fusion and WT1 Knockout in Human HSPCs
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia
Developmental Context Dictates Leukemic Transformation Potential of NUP98::NSD1-Edited HSPCs
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia
Developmental Context Dictates Leukemic Transformation Potential of NUP98::NSD1-Edited HSPCs
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia
Developmental Context and Cell Type of Origin in NUP98::NSD1 Leukemia
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia
Developmental Context and Cell Type of Origin in NUP98::NSD1 Leukemia
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia
Differential Expansion of NUP98::NSD1-Positive Clones Across Ontogeny
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia
Differential Expansion of NUP98::NSD1-Positive Clones Across Ontogeny
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Table S6 from Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia
PRDM16 binding genes in NUP98::NSD1/WT1ko by ChIP-seq
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia
PRDM16 binding genes in NUP98::NSD1/WT1ko by ChIP-seq